Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;152(1):27-38.
doi: 10.1111/acps.13804. Epub 2025 Mar 27.

Prevalence and Incidence of Attention Deficit/Hyperactivity Disorder in Denmark. A National Register-Based Open Cohort Study

Simon Grøntved  1   2 , Kathrine Hald  2   3 , Christina Mohr-Jensen  1   4 , Søren Paaske Johnsen  2 , Jan Mainz  1 , Jan Brink Valentin  2
Affiliations

Prevalence and Incidence of Attention Deficit/Hyperactivity Disorder in Denmark. A National Register-Based Open Cohort Study

Simon Grøntved et al. Acta Psychiatr Scand. 2025 Jul.

Abstract

Introduction: Rises in prevalence and incidence of the neurodevelopmental disorder Attention-deficit/Hyperactivity Disorder (ADHD) have been reported globally and estimated in Denmark previously. Nevertheless, differences in methodology hinder an assessment of the temporal evolution of ADHD based on published literature. The aim of this study was to consistently calculate the yearly prevalence and incidence proportions of ADHD and the use of ADHD medication in Denmark from 2000 to 2022.

Methods: We conducted an open cohort study using register data covering the entire Danish population. We defined ADHD as either having a hospital diagnosis of ADHD (ICD-10: F90.0, F90.1, F90.8, or F98.8), or having redeemed a prescription for ADHD medication.

Results: Of the included 7,748,837 persons, 2.52% had ADHD, of whom 58.33% were males. The prevalence of ADHD has increased from 0.10% in 2000 to 3.03% in 2022. Specifically for the 18-27-year-olds, the prevalence was 8.16% for males and 6.12% for females in the year 2022. For the incidence, the same age group peaked within the females in 2022 at 1.10%, whereas the male incidence was consistently highest in the 6-18-year-olds, peaking in 2022 at 0.94%. Total use of ADHD medication in the population also increased. Methylphenidate was used by 97.58% of the ADHD medicated patients in 2000 and 70.60% in 2022. Lisdexamphetamine was the second most common in 2022, where 24.03% redeemed a prescription.

Limitations: Incidence and prevalence were calculated specifically for the Danish population and may not be directly generalizable to other countries.

Conclusions: The prevalence of ADHD has consistently increased throughout the past two decades. The main contribution to this increase is the ADHD incidence in females, especially young females in the most recent years 2020-2022. Methylphenidate was consistently the most common ADHD drug prescribed, though lisdexamphetamine use has increased in recent years.

Keywords: ADHD; attention deficit/hyperactivity disorder; incidence; prevalence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
The prevalence proportion of Attention Deficit/Hyperactivity Disorder (ADHD) in Denmark between the years 2000 and 2022. The entire population stratified by sex.
FIGURE 2
FIGURE 2
The incidence proportion of Attention Deficit/Hyperactivity Disorder (ADHD) in Denmark between the years 2000 and 2022. The entire population stratified by sex.
FIGURE 3
FIGURE 3
The prevalence proportion of Attention Deficit/Hyperactivity Disorder (ADHD) in Denmark between the years 2000 and 2022. The entire population stratified by sex and age‐group.
FIGURE 4
FIGURE 4
The incidence proportion of Attention Deficit/Hyperactivity Disorder (ADHD) in Denmark between the years 2000 and 2022. The entire population stratified by sex and age‐group.
FIGURE 5
FIGURE 5
The use of medication for Attention Deficit/Hyperactivity Disorder (ADHD) in Denmark between the years 2000 and 2022. The entire population stratified by sex and age‐group.
FIGURE 6
FIGURE 6
The use of medication for Attention Deficit/Hyperactivity Disorder (ADHD) in Denmark between the years 2000 and 2022. For all medicated patients, stratified by active ingredient in medication. Note that medications within a year does not necessarily sum to 100% as patients can redeem prescriptions for different medications within the same year.
See this image and copyright information in PMC

References

    1. American Psychiatric Association, DSM‐5 Task Force , “Diagnostic and statistical manual of mental disorders: DSM‐5” 5th ed. (American Psychiatric Publishing, 2013), 10.1176/appi.books.9780890425596. - DOI
    1. Kotsopoulos N., Connolly M. P., Sobanski E., and Postma M. J., “Assessing the Economic Burden and Benefit–Cost of Treating Attention‐Deficit Hyperactivity Disorder in Germany,” Journal of Health Economics and Outcomes Research 1, no. 3 (2013): 212–223, 10.36469/9866. - DOI - PMC - PubMed
    1. Anker E., Halmøy A., and Heir T., “Work Participation in ADHD and Associations With Social Characteristics, Education, Lifetime Depression, and ADHD Symptom Severity,” ADHD Attention Deficit and Hyperactivity Disorders 11, no. 2 (2019): 159–165, 10.1007/s12402-018-0260-2. - DOI - PubMed
    1. Danielson M. L., Holbrook J. R., Bitsko R. H., et al., “State‐Level Estimates of the Prevalence of Parent‐Reported ADHD Diagnosis and Treatment Among U.S. Children and Adolescents, 2016 to 2019,” Journal of Attention Disorders 26, no. 13 (2022): 1685–1697, 10.1177/10870547221099961. - DOI - PMC - PubMed
    1. Li T., Franke B., AriasVasquez A., and Mota N. R., “Mapping Relationships Between ADHD Genetic Liability, Stressful Life Events, and ADHD Symptoms in Healthy Adults,” American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 186, no. 4 (2021): 242–250, 10.1002/ajmg.b.32828. - DOI - PMC - PubMed

Substances